Clinical development of human vaccine candidates against Shigella flexneri: a systematic review of clinical trials.
Mosayeb Rostamian, Roya Chegene Lorestani, Tayebe Shahbazi et al.
✦ AI-curated · Sources linked
In 30 seconds
This systematic review evaluated the clinical evidence for human vaccine candidates against Shigella flexneri, focusing on safety, immunogenicity, and efficacy. Twenty-four clinical trials were analyzed, revealing that most candidates had acceptable safety profiles and induced immune responses. Notably, only one Phase III trial assessed clinical efficacy, indicating limited advancement in vaccine development.
Key findings
- Most vaccine candidates demonstrated acceptable safety profiles and induced measurable immune responses.
- Glycoconjugate vaccines consistently generated durable humoral immunity.
- Live-attenuated vaccines elicited broader mucosal and cellular immune responses.
- Only one Phase III trial evaluated clinical efficacy, highlighting limited progression in vaccine development.
Why it matters
Shigella flexneri is a significant cause of morbidity and mortality in children, particularly in low- and middle-income countries. Understanding vaccine candidates' safety and immunogenicity is crucial for developing effective prevention strategies against shigellosis.
What to keep in mind
Considerable heterogeneity in vaccine formulations, dosing schedules, and immunological endpoints limited direct comparisons across studies.